Two of the leading experts on anti-obesity drugs say the drugs are heralding a new era in medicine and could soon be used to treat a raft of other conditions.

David Ricks, the chair and chief executive of Eli Lilly, and Dr. Fatima Cody Stanford, obesity medicine physician at Massachusetts General Hospital/Harvard Medical School, talk through the groundbreaking role of GLP-1 medications in transforming the treatment of obesity, and how the drug could potentially be used to treat alcohol use disorder or other addictions.

Prince Harry on His Murdoch Tabloid Fight and Big Tech

In this limited series from the New York Times, hear conversations with business and policy leaders at the heart of today’s major stories, recorded live at the annual 'DealBook Summit' event in New York City. 

Subscribe today at nytimes.com/podcasts or on Apple Podcasts and Spotify. You can also subscribe via your favorite podcast app here https://www.nytimes.com/activate-access/audio?source=podcatcher. For more podcasts and narrated articles, download The New York Times app at nytimes.com/app.